BioCentury | Jul 18, 2020
Translation in Brief

Fate licenses rejection-resistant T cell therapies; plus a marker for anti-PD-1 treatment responsiveness, a cell proliferation control switch and more

Baylor’s engineered T cells designed to avoid immune rejection Baylor College of Medicine has granted Fate Therapeutics Inc. (NASDAQ:FATE) an exclusive license to alloimmune defense receptors, which render allogeneic cell therapies resistant to host immune...
BioCentury | Jun 27, 2019
Company News

Conserving cash, ImmunoGen to pursue narrower indication for bruised mirvetuximab

...Epithelial cell adhesion molecular; FOLR1 (FR-alpha; FOLR) -- Folate receptor 1; CD33 (SIGLEC3); ADAM9 -- ADAM metallopeptidase domain 9 Erin...
BioCentury | Jan 18, 2019
Product Development

ImmunoGen’s milestone year

...antibody platform to build ADCs. The 50-50 co-development and co-commercialization deal includes an ADC against ADAM metallopeptidase domain 9...
BioCentury | Aug 8, 2018
Distillery Therapeutics

Infectious disease

INDICATION: HIV/AIDS Cell culture studies suggest inhibiting L selectin shedding could help treat latent HIV infection. In L selectin-expressing CD4 + T cells exposed to HIV-1, a tool compound matrix metalloproteinase 1 (MMP1) inhibitor that...
BioCentury | Dec 8, 2017
Translation in Brief

ADAM and Ephrin

An October study in Nature Medicine from researchers at Harvard Medical School and the University of Montreal has shown inhibiting the cell surface protease ADAM10 could treat a form of idiopathic pulmonary fibrosis mediated by...
BioCentury | Oct 24, 2017
Distillery Therapeutics


INDICATION: Pulmonary fibrosis Mouse studies suggest inhibiting ADAM10 could help treat idiopathic pulmonary fibrosis (IPF). In a mouse model of IPF, an ADAM10 inhibitor tool compound decreased fibrosis in the lung and increased survival compared...
BioCentury | Sep 26, 2017
Distillery Therapeutics


INDICATION: Brain cancer Mouse studies suggest inhibiting ADAM10 with INCB7839 could help treat brain cancer. In a mouse model of high-grade glioma, knockout of NLGN3 -- which is activated by ADAM10-mediated cleavage from synaptic membranes...
BioCentury | Sep 20, 2017
Preclinical News

Inhibiting ADAM10 could help treat brain cancer

In a paper published in Nature , researchers at Stanford University and colleagues showed that glioma growth is dependent on neuroligin 3 (NLGN3) , and that inhibiting ADAM metallopeptidase domain 10 (ADAM10) reduced NLGN3 shedding from neurons...
BioCentury | Jul 13, 2017
Targets & Mechanisms

Insider signaling

With evidence mounting that cell surface receptors keep signaling after they are internalized, a Takeda-backed study from Monash University has shown how the phenomenon could solve the riddle of why antagonists of the substance P...
BioCentury | Dec 22, 2016
Targets & Mechanisms

Opportunity Knocks

Despite its continued emphasis on tapping external innovation for new opportunities, industry is still leaving on the table scores of unexploited drug targets identified at universities, according to an analysis of BioCentury’s BCIQ: BioCentury Online...
Items per page:
1 - 10 of 19